Advanced Solid Tumor research hub

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

This study is testing a new drug, NXP800, for people with advanced cancers. It aims to find a safe dose and see how well it works, especially for certain types of ovarian cancer that have a specific genetic change called ARID1a mutation.

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

This study looks at new treatments for ovarian cancer that has come back and is resistant to platinum-based chemotherapy. It combines existing drugs like paclitaxel and bevacizumab with a new drug called pembrolizumab, hoping to stop the cancer from growing for longer.

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

This study is looking at a new drug (INCB123667) for ovarian cancer that has become resistant to standard chemotherapy. Researchers want to see if this new drug works better than existing chemotherapy options for patients whose cancer has high levels of a protein called Cyclin E1.

Transforming Ovarian Cancer Diagnostic Pathways

This study looks at a new blood test, ROMA, for ovarian cancer. We want to see if it's better than the current CA125 test at finding cancer earlier and whether it's good value for money. It's for women whose GPs think they might have ovarian cancer.

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

This study is testing a new medicine called AZD8205, by itself or with other cancer drugs. It's for people with advanced cancers like breast, ovarian, or lung cancer, to see if it's safe and helps shrink tumours.

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

This study is looking at new treatments for a specific type of ovarian cancer that has come back or won't go away. We want to see if these treatments are safe and effective for patients whose cancer has certain genetic features.

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

This study is testing a new cancer medicine, botensilimab, sometimes with another drug, balstilimab. It's for people with advanced cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works, and find the best dose.

Clinical Pre-screening Protocol for Ovarian Cancer

This study looks at your ovarian cancer tissue to see if a special test can predict which cancer drugs might work best for you. It helps doctors understand how effective past treatments were and guide future choices.

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

This study is for women aged 18-75 with a certain type of ovarian cancer. It tests a new treatment, ADP-A2M4CD8, alone or with nivolumab, to see how well it works and if it's safe.

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

This study is for women with ovarian cancer that has come back after treatment with certain drugs (PARP inhibitors). It's looking at new combinations of medicines (tuvusertib with niraparib or lartesertib) to see how well they work and if they are safe.

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.

Trial of THEO-260 in Ovarian Cancer Patients

This study is testing a new treatment, THEO-260, for advanced ovarian cancer. It's looking for a safe dose and early signs that it can shrink tumours. Only women aged 18 and over with certain types of ovarian cancer who haven't responded to previous treatments can take part.

ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients

This study aims to create a tool to predict how well ovarian cancer patients will respond to chemotherapy. It uses samples from surgery and tracks their treatment to help doctors choose the best personal treatment plan.

A Study of MGC026 in Participants With Advanced Solid Tumors

This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.

MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm.

This study compares two ways to remove growths on ovaries or fallopian tubes: traditional open surgery and robotic surgery. It aims to see if robotic surgery is better for certain growths, especially those that might be early cancer, by looking at how patients recover.

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

This study is testing a new drug, TUB-040, for ovarian cancer and a type of lung cancer (non-small cell lung cancer) when standard treatments haven't worked. It checks how safe it is, how it moves in the body, and if it helps shrink tumours. The study aims to find the best dose.

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

This study is testing a new cancer medicine, OVM-200, for the first time in people. It involves up to 52 patients with prostate, lung, or ovarian cancer to check if it's safe and how well it works. It's given as an injection under the skin.

Ovarian Cancer Radiomics Approach in CT Led Evaluation

This study uses a new computer method, called radiomics, to analyse CT scans of ovarian cancer. It aims to see if this detailed scan analysis can help doctors plan more personalised treatment and understand the cancer better, potentially leading to new treatments.

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

This study is for women with ovarian cancer that has come back, specifically a type that has responded well to chemotherapy in the past. It's looking at a new way to give carboplatin, a common chemotherapy drug, to see if it can work better and with fewer side effects.

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

This study is looking at a new way to treat advanced ovarian cancer. It combines a drug called olaparib with standard chemotherapy (carboplatin and paclitaxel) to see if it works better and is safe compared to chemotherapy alone.

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

This study looks at the best time to have surgery for advanced ovarian cancer. It compares having surgery first, then chemotherapy, versus having some chemotherapy first, then surgery, then more chemotherapy, to see which approach works better.

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

This study is testing a new drug, BT5528, for advanced cancers like ovarian, lung, and breast cancer. We want to find a safe dose, understand side effects, and see how well it works, sometimes given with another drug called nivolumab.

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

This study is looking at a new treatment for certain types of ovarian, fallopian tube, or peritoneal cancer that have returned after initial treatment. It compares a new drug, mirvetuximab soravtansine, given with bevacizumab, against bevacizumab alone, to see if the new combination can keep the cancer away for longer.

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

This study is looking at new treatments for a specific type of ovarian cancer called low-grade serous ovarian cancer. We want to see if a new drug, avutometinib, works well alone or with another drug, defactinib, for those whose cancer has returned.

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer

A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.

Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

A Phase 1 study to evaluate the metabolism of [14C]PF-07104091 in healthy adult male participants

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

This study is testing a new treatment called Radspherin for advanced ovarian, fallopian tube, or peritoneal cancers. It aims to see how well it works and if it's safe when given with standard chemotherapy and surgery for people whose cancer is suitable for this combined approach.

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

Cancer Loyalty Card Study 2 (CLOCS-2)

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

This study is developing new blood tests for early cancer detection and to monitor how well treatment is working. It uses artificial intelligence to look at tiny particles in blood samples from people with various cancers and healthy volunteers.

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

This early-stage study is testing a new drug, MOMA-313, for advanced solid tumours, including prostate, breast, and pancreatic cancers. It aims to find a safe dose and see how it works, either alone or with another drug called Olaparib, in patients whose tumours have a specific genetic weakness.